AACR 2023 | VT3989YAP, a YAP/TEAD inhibitor, in mesothelioma and NF2-mutant cancers
Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of the first-in-call, first-in-human Phase I trial (NCT04665206) of VT3989, a YAP/TEAD inhibitor, in patients with advanced solid tumors enriched for malignant mesothelioma and other tumors with NRF2 mutations. The co-primary endpoints are occurrence of dose limiting toxicity and occurrence of general toxicity. Secondary endpoints include tumor response and pharmacokinetic evaluation. VT3989 was found to be safe and well tolerated and demonstrated antitumor activity in advanced mesothelioma and NF2-mutant cancers. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So VT3989 is a YAP-TEAD inhibitor. It’s really the first time we’ve been able to drug the YAP-TEAD pathway in the clinic. So, it’s very exciting; first in class, first in human clinical trial. We found that VT3989 was safe and well tolerated with mainly grade 1 to 2 toxicities, mainly reversible albuminuria. We found that by using intermittent schedules we were able to ameliorate this albuminuria...
So VT3989 is a YAP-TEAD inhibitor. It’s really the first time we’ve been able to drug the YAP-TEAD pathway in the clinic. So, it’s very exciting; first in class, first in human clinical trial. We found that VT3989 was safe and well tolerated with mainly grade 1 to 2 toxicities, mainly reversible albuminuria. We found that by using intermittent schedules we were able to ameliorate this albuminuria. What was exciting was we were able to see multiple patients who benefited with confirmed partial responses by RECIST criteria. So, we had six patients who had confirmed partial responses, one with an unconfirmed partial response and also patients who had disease stabilization not amounting to a partial response. And these responses were mainly seen in patients with different types of mesothelioma and also in patients with solid tumors with NF2 mutations.
Read more...
